NCT04205409 2025-11-03Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesUniversity of WashingtonPhase 2 Active not recruiting20 enrolled 12 charts
NCT01592370 2025-10-22An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaBristol-Myers SquibbPhase 1/2 Completed320 enrolled 35 charts
NCT01703949 2025-06-11Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaUniversity of WashingtonPhase 2 Active not recruiting28 enrolled
NCT06767956 2025-06-04Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell TherapyUniversity of PittsburghPhase 1/2 Not yet recruiting30 enrolled
NCT03432741 2025-05-26Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerMayo ClinicPhase 1 Terminated17 enrolled